Teleophthalmology for Diabetic Retinopathy

Recruiting in Palo Alto (17 mi)

Overseen byYao Liu, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Wisconsin, Madison

No Placebo Group

Trial Summary

What is the purpose of this trial?

This pragmatic clinical trial is being conducted to test the effectiveness of I-SITE (Implementation for Sustained Impact in Teleophthalmology), an implementation program to sustain increased diabetic eye screening rates using teleophthalmology in rural, multi-payer health systems. Up to 10 rural health systems providing teleophthalmology to 10,000 patients with diabetes and 100 clinical care personnel participating in the I-SITE intervention will be enrolled for up to 48 months.

Eligibility Criteria

This trial is for rural health systems that already have a teleophthalmology program for diabetic eye screening but with less than 50% screening rates. These systems must serve patients in areas defined as rural and agree to share de-identified patient data.

Inclusion Criteria

Health system agrees to share de-identified patient data at the requested time intervals

Health system serves rural patients as defined as those patients living in counties considered rural by the federal Office of Management and Budget (OMB)

My health system offers diabetic eye screening via telehealth.

Exclusion Criteria

Health system does not serve a rural patient population

Health system has a diabetic eye screening rate of greater than 50% (e.g., above the national average) as it may limit the ability to measure improvement from I-SITE

Treatment Details

Interventions

I-SITE (Behavioural Intervention)

Trial OverviewThe I-SITE program aims to improve diabetic eye screening rates using teleophthalmology in rural health settings. The study will involve up to 10,000 patients and 100 clinical staff across multiple sites over a period of up to 48 months.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: InterventionExperimental Treatment1 Intervention

Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.